Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial-Reference-Cited by-同舟云学术

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

Published:2023-12 Issue:12 Volume:18 Page:1743-1755
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yang James Chih-Hsin,Liu Geoffrey,Lu Shun,He Jianxing,Burotto Mauricio,Ahn Myung-Ju,Kim Dong-Wan,Liu XiaoQing,Zhao Yanqiu,Vincent Sylvie,Yin Jiani,Ma Xin,Lin Huamao M.,Popat Sanjay^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer;Gainor;Clin Cancer Res,2013

2. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

3. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer;Takeuchi;Clin Cancer Res,2009

4. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

5. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond;Ou;Drug Des Devel Ther,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

2. Bridging the Gap between Trial Adverse Events and Real-World Data;Cancer Research and Treatment;2024-07-15

3. Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL);Cancer Medicine;2024-07

4. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07

5. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review;Cancers;2024-06-26